Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

14.09
+0.10000.71%
Volume:559.18K
Turnover:7.96M
Market Cap:2.05B
PE:-5.27
High:14.50
Open:14.49
Low:13.95
Close:13.99
Loading ...

Oppenheimer Remains a Buy on Denali Therapeutics (DNLI)

TIPRANKS
·
24 Jun

Denali Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Julian Baker

Reuters
·
06 Jun

Denali Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
04 Jun

Denali Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
08 May

Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating

MT Newswires Live
·
08 May

Denali Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $32 From $80

THOMSON REUTERS
·
07 May

William Blair Keeps Their Buy Rating on Denali Therapeutics (DNLI)

TIPRANKS
·
07 May

Denali Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

BRIEF-Denali Therapeutics Q1 Operating Expenses USD 145.58 Million

Reuters
·
07 May

Denali Therapeutics Q1 Operating Income USD -145.58 Million

THOMSON REUTERS
·
07 May

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

Zacks
·
03 Apr

BUZZ-Denali Therapeutics begins marketing application for genetic disorder drug, shares rise

Reuters
·
02 Apr

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up

MT Newswires Live
·
02 Apr

Denali initiates BLA filing for accelerated approval of tividenofusp alfa

TIPRANKS
·
02 Apr

BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome

Reuters
·
02 Apr

Denali Therapeutics Announces Initiation of Bla Filing for Accelerated Approval of Tividenofusp Alfa for Treatment of Hunter Syndrome (Mps Ii) and Positive Ongoing Interactions With FDA on Dnl126 Through Start Program

THOMSON REUTERS
·
02 Apr

Denali Therapeutics : Expects to Complete Bla Submission in First Half of May 2025

THOMSON REUTERS
·
02 Apr

Denali Therapeutics Inc: Continues to Prepare for a Potential Commercial Launch in U.S. in Late 2025 or Early 2026

THOMSON REUTERS
·
02 Apr

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

GlobeNewswire
·
02 Apr

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Dow Jones
·
27 Mar